Literature DB >> 14257400

PROPRANOLOL (INDERAL) IN DISTURBANCES OF CARDIAC RHYTHM.

D J ROWLANDS, G HOWITT, P MARKMAN.   

Abstract

Entities:  

Keywords:  AURICULAR FIBRILLATION; AURICULAR FLUTTER; CORONARY DISEASE; DRUG THERAPY; HEART SEPTAL DEFECTS, ATRIAL; HYPERTHYROIDISM; RHEUMATIC HEART DISEASE; SYMPATHOLYTICS; TACHYCARDIA; TACHYCARDIA, PAROXYSMAL

Mesh:

Substances:

Year:  1965        PMID: 14257400      PMCID: PMC2165562          DOI: 10.1136/bmj.1.5439.891

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  9 in total

1.  PHARMACODYNAMIC EFFECTS OF BETA-ADRENERGIC RECEPTOR BLOCKADE IN PATIENTS WITH HYPERTHYROIDISM.

Authors:  W R WILSON; E O THEILEN; F W FLETCHER
Journal:  J Clin Invest       Date:  1964-08       Impact factor: 14.808

2.  PRONETHALOL IN TREATMENT OF VENTRICULAR ARRHYTHMIAS DURING ANAESTHESIA.

Authors:  J P PAYNE; R M SENFIELD
Journal:  Br Med J       Date:  1964-03-07

3.  A NEW ADRENERGIC BETARECEPTOR ANTAGONIST.

Authors:  J W BLACK; A F CROWTHER; R G SHANKS; L H SMITH; A C DORNHORST
Journal:  Lancet       Date:  1964-05-16       Impact factor: 79.321

4.  CARCINOGENIC ACTION OF PRONETHALOL.

Authors:  G E PAGET
Journal:  Br Med J       Date:  1963-11-16

5.  BETA-ADRENERGIC RECEPTOR BLOCKADE IN CARDIAC ARRHYTHMIAS.

Authors:  J P STOCK; N DALE
Journal:  Br Med J       Date:  1963-11-16

6.  Simplification of Haldane's apparatus for measuring carbon dioxide concentration in respired gases in clinical practice.

Authors:  E J CAMPBELL
Journal:  Br Med J       Date:  1960-02-13

7.  Cyclopropane anesthesia. II. Epinephrine and norepinephrine in initiation of ventricular arrhythmias by carbon dioxide inhalation.

Authors:  H L PRICE; A A LURIE; R E JONES; M L PRICE; H W LINDE
Journal:  Anesthesiology       Date:  1958 Sep-Oct       Impact factor: 7.892

8.  Cyclopropane anesthesia and ventricular arrhythmias.

Authors:  M JOHNSTONE
Journal:  Br Heart J       Date:  1950-07

9.  THE RAPID DISTRIBUTION OF 3H2O AND 11CO2 IN THE BODY IN RELATION TO THE IMMEDIATE CARBON DIOXIDE STORAGE CAPACITY.

Authors:  A S FOWLE; C M MATTHEWS; E J CAMPBELL
Journal:  Clin Sci       Date:  1964-08       Impact factor: 6.124

  9 in total
  22 in total

1.  Adrenergic beta-receptor blockade in hyperthyroidism.

Authors:  I Ramsay
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

2.  Adrenoceptive sites in the veins.

Authors:  T Zsoter; H Tom
Journal:  Br J Pharmacol Chemother       Date:  1967-11

Review 3.  [Adrenergic alpha and beta receptors and their specific inhibitors].

Authors:  E Muscholl; K H Rahn
Journal:  Klin Wochenschr       Date:  1968-02-01

4.  [Cardiac effects ofprenylamine and iproveratril in comparison with propanolol, pronethalol an ajmaline].

Authors:  W Schaumann; R Bodem; W Bartsch
Journal:  Naunyn Schmiedebergs Arch Pharmakol Exp Pathol       Date:  1966

5.  A trial of propranolol in myocardial infarction.

Authors:  J R Ledwich
Journal:  Can Med Assoc J       Date:  1968-05-25       Impact factor: 8.262

6.  Effect of propranolol on exercise tolerance of patients with atrial fibrillation.

Authors:  R W Brown; A J Goble
Journal:  Br Med J       Date:  1969-05-03

7.  Effects of (plus or minus)-propranolol, (plus or minus)-,(plus)-, and (minus)-alprenolol on unanaesthetized dogs with ventricular arrhythmias resulting from coronary artery ligation.

Authors:  B R Duce; L Garberg; E R Smith
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

8.  Haemodynamic effects of propranolol (Inderal) in acute myocardial infarction.

Authors:  G Bay; P Lund-Larsen; E Lorentsen; E Sivertssen
Journal:  Br Med J       Date:  1967-01-21

9.  Comparison of propranolol and LB 46 (prinodolol) on hyperthyroid tachycardia.

Authors:  A G Arbab; P Turner
Journal:  Postgrad Med J       Date:  1971-06       Impact factor: 2.401

Review 10.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.